Exclusive Financial Advisor to the Special Committee of the Board of Directors of Reunion Neuroscience Inc.
Oppenheimer & Co. Inc. Acted as Exclusive Financial Advisor to the Special Committee of the Board of Directors of Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) on its Take-Private Transaction with MPM BioImpact
Reunion Neuroscience is a clinical stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound, is being developed as a potential treatment for postpartum depression that could provide rapid symptom relief and durable efficacy. Reunion is also developing the RE200 series, which includes preclinical compounds with enhanced receptor selectivity to address additional therapeutic applications.
MPM BioImpact is a leading biotechnology investment firm that invests across the biotech landscape with its early-stage venture capital funds and impact funds that invest in both private and public companies.
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 5721598.1